<DOC>
	<DOCNO>NCT02702414</DOCNO>
	<brief_summary>This efficacy safety study pembrolizumab ( MK-3475 , KEYTRUDA® ) monotherapy participant previously systemically treated hepatocellular carcinoma ( HCC ) . Study participant may receive pembrolizumab every 3 week 35 administration ( approximately 2 year ) . The primary objective study determine Objective Response Rate ( ORR ) pembrolizumab give monotherapy participant previously systemically treat HCC</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Monotherapy Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma ( MK-3475-224/KEYNOTE-224 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has histologically cytologically confirm diagnosis HCC ( fibrolamellar mixed hepatocellular/cholangiocarcinoma subtypes eligible ) base pathology report . Has Barcelona Clinic Liver Cancer ( BCLC ) Stage C disease BCLC Stage B disease amenable locoregional therapy refractory locoregional therapy , amenable curative treatment approach . Has ChildPugh Class A liver score within 7 day first dose study drug . Has predict life expectancy &gt; 3 month . Has measurable disease base Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 confirm blinded central image vendor . Has performance status 0 1 use Eastern Cooperative Oncology Group ( ECOG ) Performance Scale within 7 day first dose study drug . Has document objective radiographic progression stop treatment sorafenib else intolerance sorafenib . Participants chronic infection Hepatitis C Virus ( HCV ) untreated allow study . In addition , participant successful HCV treatment ( define sustain virologic response [ SVR ] 12 SVR 24 ) allow long 4 week pass completion HCV therapy start study drug . Is willing use adequate method contraception course study 120 day last dose study drug ( male female participant childbearing potential ) . Demonstrates adequate organ function . Is currently participate receive study therapy participate study investigational agent receive study therapy , herbal/complementary oral IV medicine , use investigational device within 4 week first dose study drug . Participant must also recover associated therapy ( i.e. , Grade ≤1 baseline ) adverse event due prior therapy . Has receive sorafenib within 14 day first dose study drug . Has esophageal gastric variceal bleeding within last 6 month . Has clinically apparent ascites physical examination . Has portal vein invasion main portal branch ( Vp4 ) , inferior vena cava , cardiac involvement HCC base imaging . Has encephalopathy last 6 month . Participants rifaximin lactulose control encephalopathy allow . Had solid organ hematologic transplant . Had prior systemic therapy HCC sorafenib , intercurrent local therapy liver tumor sorafenib study drug . Has active autoimmune disease require systemic treatment past 2 year ( i.e. , use diseasemodifying agent , corticosteroid , immunosuppressive drug ) . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study drug . Has receive locoregional therapy liver ( transcatheter chemoembolization [ TACE ] , transcatheter embolization [ TAE ] , radiation , radioembolization , ablation ) major surgery liver site within 6 week prior first dose study drug . Minor surgery ( e.g. , simple excision , tooth extraction ) must occur least 7 day prior first dose study drug ( Cycle 1 , Day 1 ) . Participants must recover adequately ( i.e. , Grade ≤1 baseline ) toxicity and/or complication intervention prior start study drug . Has diagnose additional malignancy within 5 year prior first dose study treatment exception curatively treat basal cell carcinoma skin , squamous cell carcinoma skin and/or curatively resect situ cervical and/or breast cancer . Has radiographically detectable central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has evidence history interstitial lung disease active noninfectious pneumonitis . Has active infection require systemic therapy . Has know psychiatric substance abuse disorder would interfere cooperation requirement study . Is pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose trial treatment . Has receive prior immunotherapy include antiprogrammed death1 ( antiPD1 ) , antiPDligand1 ( antiPDL1 ) , antiPDL2 agent , participant previously participate Merck pembrolizumab ( MK3475 ) clinical stduies . Has know history human immunodeficiency virus ( HIV ) Has untreated active Hepatitis B ( HBV ) . Has dual infection HBV/HCV hepatitis combination study entry . Has receive live vaccine within 30 day plan start study drug ( Cycle 1 , Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>